View Older Stories View More Recent Stories

May 7, 2021 01:00AM argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021
Apr 28, 2021 01:00AM argenx Management to Present at Upcoming Virtual Investor Conferences
Mar 30, 2021 04:00PM argenx announces Annual General Meeting of Shareholders on May 11, 2021
Mar 4, 2021 01:00AM argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update
Mar 2, 2021 02:00AM argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis
Feb 25, 2021 01:00AM argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021
Jan 6, 2021 04:01PM argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
Jan 6, 2021 04:01PM argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
Dec 17, 2018 02:30AM Forbion Portfolio Company Staten Biotechnology Enters into a Collaboration with Novo Nordisk to Develop Novel Treatment for Dyslipidaemia
Aug 22, 2018 06:01AM argenx (ARGX) Reports Exclusive Option Exercise by AbbVie (ABBV) to Develop and License ARGX-115
Aug 22, 2018 02:01AM argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody
May 18, 2017 06:00AM argenx (Nasdaq: ARGX) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its IPO
Apr 21, 2016 06:28AM AbbVie (ABBV), argenx Enter Collaboration on ARGX-115 Against Novel Immuno-Oncology Target
Apr 21, 2016 01:07AM AbbVie and argenx to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target
Apr 21, 2016 01:00AM argenx and AbbVie to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target
View More Recent Stories View Older Stories